Skip to main content
OpenTrials
Completed

NCT Number: NCT02308761

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

RO6870810 (formerly TEN-010) is a small molecule, bromodomain and extra-terminal (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of RO6870810 monotherapy in participants with relapsed/refractory acute myeloid leukemia (RR-AML) and hypomethylating agent (HMA)-refractory myelodysplastic syndrome (MDS). The study will consist of a Screening Period, Treatment Period, and Post-Treatment Period. A standard 3+3 design will be used in which successive cohorts of three or more participants with RR-AML or HMA-refractory MDS will be treated at escalating doses until a maximum tolerated dose (MTD) is identified. Up to 51 adult participants with AML or MDS will be enrolled in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndromes Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • RR-AML
  • Relapsed/refractory MDS
  • Participants with a history of allogeneic stem cell transplant are eligible for study participation provided the following eligibility criteria are met:
  • Transplant was more than (>) 100 days prior to study enrollment
  • Participant has not taken immunosuppressive medications for at least 2 weeks
  • No signs or symptoms of graft versus host disease other than Grade 1 skin involvement
  • No active infection
  • Eastern Cooperative Oncology Group Performance Status score equal to or less than (<=) 2
  • Life expectancy of at least 2 months
  • Disease-free of active second/secondary or prior malignancies for equal to or more than (>=) 1 year with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast
  • Adequate hematological, renal, hepatic and coagulation laboratory test results
  • Women of childbearing potential and men must agree to use adequate contraception from 28 days prior to the first dose of the study drug, during the entire Treatment Period, and for at least 28 days after the last dose of the study drug

Exclusion criteria

  • New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia
  • Have Fridericia-corrected QT interval > 470 milliseconds (msec) (female) or > 450 msec (male), or history of congenital long QT syndrome
  • Uncontrolled bacterial, viral, or fungal infections
  • Known clinically important respiratory impairment
  • Positive for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C antibodies
  • History of major organ transplant
  • Symptomatic central nervous system disease, malignancy, or metastasis
  • Pregnant or nursing
  • Concomitant chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormonal therapy
  • Treatment with surgery or chemotherapy within 21 days prior to study entry
  • Prior treatment with small molecule bromodomain and extra terminal family inhibitor
  • Radiation for symptomatic lesions within 14 days of study enrollment
  • Active substance abuse

Treatment and study plan

RO6870810

Drug

Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.

Primary outcomes

  1. Percentage of Participants With Dose-Limiting Toxicities (DLTs)

    Time frame: Cycle 1 (cycle length = 21 or 28 days)

  2. MTD of RO6870810

    Time frame: Cycle 1 (cycle length = 21 or 28 days)

  3. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline up to 30 days after last dose (up to approximately 2.75 years)

Secondary outcomes

  1. Area Under the Concentration Versus Time Curve from Time Zero to the End of Dosing Interval 24 Hours Later (AUC0-24) of RO6870810

    Time frame: Cycle 1 Day 1 up to 2.75 years (detailed timeframe is provided in outcome description)

    Predose (Hour 0), immediately postdose and 0.25, 0.5, 1, 2, 4 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 22 (Cycle 1 Day 22 is applicable only for 28-day continuous treatment); Predose (Hour 0), 4 hours postdose on Cycle 1 Day 2; Days 8, 15 of Cycle 1; Predose (Hour 0) on Day 1 of each treatment cycle from Cycle 2 up to end of treatment (approximately 2.75 years) (Cycle length = 21 or 28 days)

  2. Maximum Observed Plasma Concentration (Cmax) of RO6870810

    Time frame: Cycle 1 Day 1 up to 2.75 years (detailed timeframe is provided in outcome description)

    Predose (Hour 0), immediately postdose and 0.25, 0.5, 1, 2, 4 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 22 (Cycle 1 Day 22 is applicable only for 28-day continuous treatment); Predose (Hour 0), 4 hours postdose on Cycle 1 Day 2; Days 8, 15 of Cycle 1; Predose (Hour 0) on Day 1 of each treatment cycle from Cycle 2 up to end of treatment (approximately 2.75 years) (Cycle length = 21 or 28 days)

  3. Time to Cmax (Tmax) of RO6870810

    Time frame: Cycle 1 Day 1 up to 2.75 years (detailed timeframe is provided in outcome description)

    Predose (Hour 0), immediately postdose and 0.25, 0.5, 1, 2, 4 hours postdose on Cycle 1 Day 1 and Cycle 1 Day 22 (Cycle 1 Day 22 is applicable only for 28-day continuous treatment); Predose (Hour 0), 4 hours postdose on Cycle 1 Day 2; Days 8, 15 of Cycle 1; Predose (Hour 0) on Day 1 of each treatment cycle from Cycle 2 up to end of treatment (approximately 2.75 years) (Cycle length = 21 or 28 days)

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Dose Escalation Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Dec 4, 2014
Registry last updated
Dec 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.